Sanofi Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Sanofi key operating metrics including Phase II Trials Products (Oncology), environmental, and social and governance score (ESG).

Phase II Trials Products (Oncology)

100.0%

FY, 2021

Phase III/Filed Trials Products (Oncology)

66.7%

FY, 2021

Phase I Trials Products (Rare Blood Disorders)

FY, 2020

Operating Metrics

Metrics	FY, 2018	FY, 2019	FY, 2020	FY, 2021
Phase II Trials Products (Oncology)	5	6	6	12
Phase III/Filed Trials Products (Oncology)	7	8	6	2
Phase I Trials Products (Rare Blood Disorders)	4	4	4
Phase III/Filed Trials Products (Rare Blood Disorders)	2	4	4	5
Phase I Trials Products (Immunology and Inflamation)	1	3	3	7
Phase II Trials Products (Immunology and Inflamation)	8	8	1	8
Phase III/Filed Trials Products (Immunology and Inflamation)	6	9	3	1
Phase I Trials Products (Multiple Sclerosis Neurology)	2	2	2	1
Projects in R&D Pipeline	81	91
Phase II Trials Products (Multiple Sclerosis Neurology)	2	3	1	2
Phase III/Filed Trials Products (Multiple Sclerosis Neurology)	2	2	3	4
Phase II Trials Products (Rare Diseases)	4	4	4	3
Phase III/Filed Trials Products (Rare Diseases)	3	3	3	3
Phase I Trials Products (Vaccines)	3	4	2
Phase II Trials Products (Vaccines)	4	1	4	4
Phase III Trials Products (Vaccines)	4	5	3	5
Suppliers	86K	68K
Phase I Trials Products (Oncology)	6	10	12	9
R&D Centers	20	20
Production Sites	75	73
Phase III/Filed Trials Products (Diabetes and Cardiovascular)	7	4
Filed Trials Products (Vaccines)		2	1	1
Phase I Trials Products (Rare Diseases)			1	2

60-79 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub